EcoDrugPlus

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSMZEG00005006735
Gene Symbol: LOC101478402
3 Cross references
212 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSMZEG00005027057
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 3

Ensembl ID : ENSMZEG00005009989
Gene Symbol: LOC101475861
4 Cross references
161 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSMZEG00005010012
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSMZEG00005016309
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSMZEG00005001042
Gene Symbol: EGLN3
1 Cross references
191 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSMZEG00005027275
Gene Symbol: EPAS1
3 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSMZEG00005001292
Gene Symbol: ECE1
3 Cross references
229 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSMZEG00005009114
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMZEG00005008877
Gene Symbol: LOC101471769
4 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMZEG00005002828
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMZEG00005010301
Gene Symbol: EDNRB
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).